Comprehensive analytical approach identifies a subtype of CTCF+ tumor-associated neutrophils associated with CRC development and as a biomarker for immunotherapy

综合分析方法鉴定出一种与结直肠癌发展相关的CTCF+肿瘤相关中性粒细胞亚型,并将其作为免疫治疗的生物标志物。

阅读:1

Abstract

Background: Colorectal cancer (CRC) is an aggressive and heterogeneous tumor with limited therapeutic options. Tumor-associated neutrophils (TANs) play multifaceted roles in the tumor microenvironment (TME) depending on their polarization. Understanding TAN heterogeneity and the mechanisms underlying their tumor-promoting activities is critical for advancing CRC treatment. Methods: This study integrated single-cell RNA sequencing, spatial transcriptomics, bulk RNA sequencing, and in vivo/ex vivo experiments to characterize TANs in CRC. Results: We identified a distinct subpopulation of TANs characterized by high CCCTC-binding factor (CTCF) expression (CTCF+ TANs) enriched in hypoxic tumor regions. CTCF+ TANs exhibit enhanced migratory capacity and IL-1β secretion, correlating with poor prognosis and resistance to immunotherapy. Mechanistically, CTCF regulates the expression of Migration and Invasion Enhancer 1 (MIEN1), which promotes TAN recruitment and migration without triggering inflammation. Functional studies revealed that CTCF+ TANs suppress T-cell immunity, facilitate epithelial-to-mesenchymal transition (EMT), and contribute to CRC progression and metastasis. In vivo, targeting CTCF-MIEN1-IL-1β signaling rescued the immunosuppressive microenvironment and improved the efficacy of anti-PD-L1 therapy. Conclusions: CTCF+ TANs represent a novel TAN subtype that drives CRC progression and immunosuppression via the CTCF-MIEN1-IL-1β axis. These findings highlight the potential of targeting CTCF+ TANs to overcome immunotherapy resistance and improve patient outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。